ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 19.0% in December

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 577,200 shares, a growth of 19.0% from the November 30th total of 484,900 shares. Currently, 1.1% of the company's stock are sold short. Based on an average daily trading volume, of 139,700 shares, the short-interest ratio is presently 4.1 days.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. JMP Securities began coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They set an "outperform" rating and a $33.00 price objective for the company. Citizens Jmp raised shares of ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $38.67.

ABIVAX Société Anonyme Trading Down 7.0 %

ABIVAX Société Anonyme stock traded down $0.54 during midday trading on Friday, reaching $7.12. The company's stock had a trading volume of 338,692 shares, compared to its average volume of 98,969. The stock's 50-day simple moving average is $9.06 and its 200-day simple moving average is $10.90. ABIVAX Société Anonyme has a 52-week low of $6.65 and a 52-week high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its stake in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Walleye Capital LLC raised its stake in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after purchasing an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after purchasing an additional 119,300 shares during the period. Finally, abrdn plc lifted its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.